Biogen and City Therapeutics Forge $1 Billion+ RNAi Partnership to Transform CNS Drug Development

Biogen Inc. and City Therapeutics, Inc., a pioneer in next-generation RNAi, have formed a strategic research partnership to develop RNA interference (RNAi)-based therapeutics for central nervous system (CNS) disorders.

Deal Highlights:

• City Therapeutics will receive an initial investment of $46 million and an equity investment in the form of a convertible note.
• Potential for over $1 billion in future milestone payments
• Additional royalties tied to commercial success
• Biogen has acquired exclusive rights to one central nervous system (CNS) target, with the potential to expand to a second

City Therapeutics’ innovative RNAi trigger engineering and Biogen’s global medication development and commercialization capabilities are combined in this high-impact collaboration. The initial focus will be on a single CNS illness target, with the potential for the expansion to other targets contingent upon the results. Biogen will supervise regulatory activities, commercialization strategies, and IND-enabling investigations.

This collaboration is consistent with Biogen’s evolving research and development strategy, which is designed to strike a balance between targeted external investments and internal innovation. The collaboration underscores the increasing significance of RNAi as a therapeutic approach, particularly for precision-targeting in neurological disorders, where delivery and specificity continue to be significant obstacles.

Market Impact:

This partnership is anticipated to enhance the trust of investors and researchers and developers in the RNAi industry, which is anticipated to reach USD 20 billion by 2030. Our collaboration has the potential to facilitate the development of a new generation of discoveries in neurodegenerative disease therapy by resolving the delivery challenges associated with CNS-targeted RNAi therapeutics. Pharmaceutical and biotechnology companies are anticipated to demonstrate increased interest, as well as increased licensing and M&A activity in the RNAi domain.